Precigen is a life sciences company focused on developing bio-therapeutic control systems that minimize toxicity in therapeutic applications. Their technology aims to enhance the safety and efficacy of treatments by precisely regulating the delivery and activity of bio-therapeutics.
Funding
$79M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current therapeutic approaches often lack the precision needed to target diseases effectively while minimizing off-target effects and systemic toxicity. This is particularly challenging in immuno-oncology, autoimmune disorders, and infectious diseases, where modulating the immune system requires a high degree of control.
Solution
Precigen is a biopharmaceutical company focused on developing next-generation gene and cell therapies that address urgent and intractable diseases with greater precision. The company leverages non-viral and viral expression systems, genome, DNA, RNA, and protein engineering, along with proprietary bioengineering switch technologies, to control gene expression and regulation. This approach enables the creation of potent, on-target gene and cell therapies with improved safety and efficacy profiles. Precigen's technology platforms, such as AdenoVerse and UltraCAR-T, are designed to work in combination, enhancing both efficacy and safety in therapeutic applications.
Target Audience
Precigen's therapies target patients with urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases, as well as physicians seeking pre-approval access to investigational therapies.
Features
- AdenoVerse platform: Utilizes a library of proprietary adenoviral vectors for efficient gene delivery of vaccine antigens and cytokines, featuring large payload capacity and the ability for repeat administration.
- UltraCAR-T platform: Employs a non-viral Sleeping Beauty system for multigene delivery, enabling rapid manufacturing and enhanced in vivo persistence of CAR-T cells.
- UltraVector DNA construction platform: Incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs.
- Proprietary kill switches: Allows selective elimination of cell therapies in vivo via administration of a kill switch activator, improving the safety profile.
- Membrane-bound interleukin-15 (mbIL15): A proprietary chimeric cytokine engineered to be tethered to the cell surface, enhancing the expansion and persistence of immune cells.
- UltraPorator: A high-throughput, semi-closed electroporation system designed to reduce processing time and contamination risk in cell therapy manufacturing.